The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program

被引：2
|
作者：
Silberstein, S. [1 ]
Dodick, D. W. [2 ]
DeGryse, R. E. [3 ]
Lipton, R. [4 ]
Turkel, C. C. [3 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
[4] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2013年 / 14卷
关键词：
Migraine; Treatment Cycle; Chronic Migraine; Migraine Patient; Responder Rate;
D O I：
10.1186/1129-2377-14-S1-P200
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] OnabotulinumtoxinA for Treatment of Chronic Migraine
    Markert, Ronald J.
    Solomon, Glen D.
    HEADACHE, 2011, 51 (06): : 1002 - 1003
  • [42] Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
    Aurora, Sheena
    Diener, Hans-Christoph
    Dodick, David
    JOURNAL OF HEADACHE AND PAIN, 2011, 12 (02): : 137 - 138
  • [43] Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
    Sheena Aurora
    Hans-Christoph Diener
    David Dodick
    The Journal of Headache and Pain, 2011, 12 : 137 - 138
  • [44] Efficacy, tolerability, and safety of onabotulinumtoxinA treatment for chronic migraine in patients with acute medication overuse: analysis of the PREEMPT and COMPEL trials
    Agosti, R.
    Straube, A.
    Diener, H. C.
    Freeman, M.
    Pascual Gomez, J.
    Seminerio, M.
    Delahaye, L.
    Stark, R. J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [45] OnabotulinumtoxinA Treatment Satisfaction among Patients with Chronic Migraine
    Tockhorn-Heidenreich, A.
    Ford, J.
    Jackson, J.
    Ye, W. Wenyu
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 891 - 891
  • [46] Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice"
    Blumenfeld, Andrew M.
    Silberstein, Stephen D.
    HEADACHE, 2020, 60 (10): : 2597 - 2599
  • [47] OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
    HC Diener
    DW Dodick
    RE DeGryse
    CC Turkel
    The Journal of Headache and Pain, 2013, 14
  • [48] OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
    Diener, H. C.
    Dodick, D. W.
    DeGryse, R. E.
    Turkel, C. C.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [49] OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline
    Silberstein, Stephen D.
    Blumenfeld, Andrew M.
    Cady, Roger K.
    Turner, Ira M.
    Lipton, Richard B.
    Diener, Hans-Christoph
    Aurora, Sheena K.
    Sirimanne, Mai
    DeGryse, Ronald E.
    Turkel, Catherine C.
    Dodick, David W.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 331 (1-2) : 48 - 56
  • [50] OnabotulinumtoxinA injection in the treatment of chronic migraine
    Wang, Yen-Feng
    UPDATE ON EMERGING TREATMENTS FOR MIGRAINE, 2020, 255 : 171 - 206
12345